Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.

Publication Type:



The Journal of infectious diseases, Volume 207 Suppl 1, p.S7-S12 (2013)


Clinical Trials as Topicdigestive disease, digestive deseases Hepacivirusdigestive disease, digestive deseases Hepatitis Cdigestive disease, digestive deseases Humansdigestive disease, digestive deseases Immunotherapydigestive disease, digestive deseases T-Lymphocytesdigestive disease, digestive deseases Viral Vaccines


Infection with hepatitis C virus (HCV) typically leads to persistent infection, with >170 million people estimated to be affected worldwide, putting them at risk for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Importantly, 20%-30% of individuals are able to control the virus spontaneously, usually within 6 months of exposure. This suggests that HCV vaccines and immunotherapies are a distinct possibility. We discuss here the role of T cells in controlling HCV, the gaps in our understanding of protective HCV immunity, and the recent introduction of a HCV T-cell vaccine into clinical trials.